CN113736811B - 促进tshs、yncE基因胞外表达的质粒及其构建方法和应用 - Google Patents
促进tshs、yncE基因胞外表达的质粒及其构建方法和应用 Download PDFInfo
- Publication number
- CN113736811B CN113736811B CN202110911262.3A CN202110911262A CN113736811B CN 113736811 B CN113736811 B CN 113736811B CN 202110911262 A CN202110911262 A CN 202110911262A CN 113736811 B CN113736811 B CN 113736811B
- Authority
- CN
- China
- Prior art keywords
- gene
- tsh
- plasmid
- ynce
- bor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013612 plasmid Substances 0.000 title claims abstract description 226
- 230000014509 gene expression Effects 0.000 title claims abstract description 60
- 238000010276 construction Methods 0.000 title claims abstract description 15
- 230000001737 promoting effect Effects 0.000 title abstract description 14
- 101150106423 yncE gene Proteins 0.000 title description 95
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 162
- 238000000034 method Methods 0.000 claims abstract description 62
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 61
- 101150084075 tsh gene Proteins 0.000 claims abstract description 52
- 241000894006 Bacteria Species 0.000 claims abstract description 28
- 229960005486 vaccine Drugs 0.000 claims abstract description 17
- 238000010367 cloning Methods 0.000 claims abstract description 15
- 101150101685 bor gene Proteins 0.000 claims description 115
- 238000001976 enzyme digestion Methods 0.000 claims description 42
- 238000011144 upstream manufacturing Methods 0.000 claims description 38
- 238000012258 culturing Methods 0.000 claims description 33
- 241000588724 Escherichia coli Species 0.000 claims description 29
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 25
- 241000271566 Aves Species 0.000 claims description 23
- 239000013599 cloning vector Substances 0.000 claims description 22
- 238000012408 PCR amplification Methods 0.000 claims description 21
- 230000003321 amplification Effects 0.000 claims description 21
- 230000001717 pathogenic effect Effects 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 18
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims description 9
- 239000006166 lysate Substances 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- 238000010353 genetic engineering Methods 0.000 claims description 7
- 238000011081 inoculation Methods 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 230000009466 transformation Effects 0.000 claims description 7
- 238000009835 boiling Methods 0.000 claims description 5
- 244000144977 poultry Species 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 238000010348 incorporation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 17
- 239000000185 hemagglutinin Substances 0.000 abstract description 10
- 101710154606 Hemagglutinin Proteins 0.000 abstract description 9
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract description 9
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract description 9
- 101710176177 Protein A56 Proteins 0.000 abstract description 9
- 239000012636 effector Substances 0.000 abstract description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- -1 wherein Proteins 0.000 abstract 1
- 239000000047 product Substances 0.000 description 46
- 108020004414 DNA Proteins 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 41
- 230000006698 induction Effects 0.000 description 40
- 238000001514 detection method Methods 0.000 description 35
- 238000000246 agarose gel electrophoresis Methods 0.000 description 28
- 238000003776 cleavage reaction Methods 0.000 description 25
- 230000007017 scission Effects 0.000 description 25
- 238000005520 cutting process Methods 0.000 description 20
- 239000006228 supernatant Substances 0.000 description 20
- 239000000499 gel Substances 0.000 description 18
- 238000011084 recovery Methods 0.000 description 16
- 230000001580 bacterial effect Effects 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 230000029087 digestion Effects 0.000 description 14
- 238000000137 annealing Methods 0.000 description 13
- 238000001962 electrophoresis Methods 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 239000002609 medium Substances 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 241000287828 Gallus gallus Species 0.000 description 10
- 238000004925 denaturation Methods 0.000 description 10
- 230000036425 denaturation Effects 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 238000012257 pre-denaturation Methods 0.000 description 10
- 235000013330 chicken meat Nutrition 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 238000001556 precipitation Methods 0.000 description 9
- 230000001131 transforming effect Effects 0.000 description 9
- 239000013642 negative control Substances 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 230000035939 shock Effects 0.000 description 7
- 238000013461 design Methods 0.000 description 6
- 241001052560 Thallis Species 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 235000013594 poultry meat Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000011426 transformation method Methods 0.000 description 4
- 230000004544 DNA amplification Effects 0.000 description 3
- 101710188807 Lipoprotein bor Proteins 0.000 description 3
- 101800002848 Temperature-sensitive hemagglutinin tsh Proteins 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229960001212 bacterial vaccine Drugs 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 241001135756 Alphaproteobacteria Species 0.000 description 1
- 241001605719 Appias drusilla Species 0.000 description 1
- 101100460704 Aspergillus sp. (strain MF297-2) notI gene Proteins 0.000 description 1
- 108010055991 BglII endonuclease Proteins 0.000 description 1
- 108010089921 CTCGAG-specific type II deoxyribonucleases Proteins 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010071301 Perihepatitis Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 101150098159 TSHR gene Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 101150046414 ce gene Proteins 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 208000023406 head swelling Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000001937 non-anti-biotic effect Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 235000013613 poultry product Nutrition 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (8)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021108759496 | 2021-07-30 | ||
CN202110875949 | 2021-07-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113736811A CN113736811A (zh) | 2021-12-03 |
CN113736811B true CN113736811B (zh) | 2023-07-18 |
Family
ID=78730474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110911262.3A Active CN113736811B (zh) | 2021-07-30 | 2021-08-10 | 促进tshs、yncE基因胞外表达的质粒及其构建方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113736811B (zh) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2015DN02393A (zh) * | 2012-09-24 | 2015-09-04 | Hebei Kexing Pharma Co Ltd | |
CN107557375A (zh) * | 2017-07-14 | 2018-01-09 | 河北科星药业有限公司 | tsh和iss双基因共表达菌株的构建方法及其应用 |
-
2021
- 2021-08-10 CN CN202110911262.3A patent/CN113736811B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN113736811A (zh) | 2021-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105801707B (zh) | 一种草鱼出血病口服疫苗及其制备与应用 | |
CN113943714B (zh) | 一种猫杯状病毒毒株及其应用 | |
CN109321535A (zh) | 一种热稳定的新城疫病毒弱毒疫苗候选株 | |
CN113248574A (zh) | 一种高效表达a型塞内卡病毒结构蛋白的方法 | |
CN101880647B (zh) | 重组猪霍乱沙门氏菌及二价基因工程疫苗与应用 | |
CN111773383B (zh) | 一种o型口蹄疫亚单位疫苗及其制备方法和应用 | |
CN104988107B (zh) | 一种高效表达口蹄疫病毒抗原基因的重组乳酸杆菌及其制备方法和应用 | |
CN111925426B (zh) | 一种产气荚膜梭菌α毒素突变体、表达系统、制备方法及应用 | |
CN117431200A (zh) | 一种在芽孢表面展示新城疫病毒hn蛋白的重组枯草芽孢杆菌、构建方法及应用 | |
CN113736811B (zh) | 促进tshs、yncE基因胞外表达的质粒及其构建方法和应用 | |
CN110016457B (zh) | 一株重组细粒棘球蚴Eg95基因的粗糙型布鲁氏菌及其疫苗生产方法 | |
CN104292338A (zh) | 含sars病毒n抗原的重组蛋白及展示n蛋白的杆状病毒 | |
CN116162637A (zh) | 一种融合基因、其所编码的蛋白及其在鱼类虹彩病毒和弹状病毒二联口服疫苗的应用 | |
CN111961121B (zh) | 产气荚膜梭菌ε毒素突变体蛋白及其制备方法、应用和疫苗 | |
CN112076314B (zh) | 一种a型口蹄疫亚单位疫苗及其制备方法和应用 | |
US11952400B2 (en) | Bovine rotavirus fusion protein and calf diarrhea multivalent vaccine | |
CN111925449B (zh) | 一种表达鸡vp2和鸡gal-1融合蛋白的重组cho细胞株及其构建方法和应用 | |
CN111944028B (zh) | 产气荚膜梭菌β毒素突变体蛋白及其制备方法、应用和疫苗 | |
CN110101854B (zh) | 一种鲤疱疹病毒ⅲ型疫苗及其制备方法 | |
CN110699328B (zh) | 一种b型猪肠道病毒及其应用 | |
Seyed Sayyah et al. | Cloning of Clostridium perfringens iota toxin gene in Escherichia coli | |
CN112076313A (zh) | 一种口蹄疫亚单位疫苗及其制备方法和应用 | |
CN107625960B (zh) | 一种通用型猪大肠杆菌病疫苗及其制备方法 | |
CN107245105B (zh) | HN-VP233-221aa融合蛋白及其制备方法和应用 | |
CN111635910A (zh) | 大熊猫轮状病毒ch-1株vp7阳性质粒及其构建方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20211203 Assignee: HEBEI GREENLAND ANIMAL PHARMACEUTICAL Co.,Ltd. Assignor: HEBEI KEXING PHARMACEUTICAL Co.,Ltd. Contract record no.: X2024980002827 Denomination of invention: Plasmids promoting extracellular expression of tshs and yncE genes and their construction methods and applications Granted publication date: 20230718 License type: Common License Record date: 20240314 Application publication date: 20211203 Assignee: Hebei jianjiale duck industry Co.,Ltd. Assignor: HEBEI KEXING PHARMACEUTICAL Co.,Ltd. Contract record no.: X2024980002825 Denomination of invention: Plasmids promoting extracellular expression of tshs and yncE genes and their construction methods and applications Granted publication date: 20230718 License type: Common License Record date: 20240313 Application publication date: 20211203 Assignee: Shijiazhuang Huifeng Animal Health Products Co.,Ltd. Assignor: HEBEI KEXING PHARMACEUTICAL Co.,Ltd. Contract record no.: X2024980002822 Denomination of invention: Plasmids promoting extracellular expression of tshs and yncE genes and their construction methods and applications Granted publication date: 20230718 License type: Common License Record date: 20240313 |